Navigation Links
LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
Date:11/6/2012

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.  The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, lead investigator in the recently completed study.

"The results from this trial demonstrate potential benefits of inhibiting SGLT1 in addition to the known effects of SGLT2 inhibition, not only in improving glycemic control, but also in achieving reductions in important cardiovascular risk factors such as blood pressure and body weight with an apparent favorable safety profile that will need confirmation by long-term controlled trials," said Dr. Rosenstock.  

LX4211, an investigational, oral, dual inhibitor of sodium glucose co-transporters 1 and 2 (SGLT1 and SGLT2), reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. In the trial, LX4211 was tested in 299 patients with poorly controlled type 2 diabetes on metformin therapy. Patients were randomized to receive LX4211 at doses of 75 mg QD, 200 mg QD, 200 mg BID, 400 mg QD, or placebo for 12 weeks. New data presented today showed that maximal 24-hour urinary glucose excretion occurred at 200 mg QD dose, whereas maximal HbA1c reduction was obtained at the 400 mg QD dose. This suggests that dual
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
2. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
3. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
6. Isis Announces Expedited Development Of ISIS-TTR Rx And Amendment To The Collaboration With GSK To Support Phase 2/3 Study
7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
8. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
9. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
10. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ), today ... Chief Executive Officer, will preside over the NASDAQ Stock ... day of Breast Cancer Awareness Month. In his remarks, ... the important benefits of Hologic,s 3D Mammography technology, the ... superior to traditional mammography. This is the ...
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
... BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, ... multinational clinical research organization (CRO) conducting studies in over ... and biotechnology companies, today announced that it has appointed ... 7, 2009. Ms. Laitinen, age 43, will replace ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... occasion of the Leishmaniasis East Africa Platform meeting, ... leishmaniasis experts, results of a pharmacovigilance or ... carried out by MSF, DNDi, and national partners ... to key decision makers in order to boost ... combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... ... of MD Anderson will be conducting a lecture on Radiation Therapy Options for Mesothelioma patients. ... ... -- Mesothelioma lecture on Tuesday November 10th, 2009, 5:30 pm CST, MesoCare.org is ...
... ... collaborating to provide Davis Applied Technology College with a working showroom of CNC machines. ... Okuma open-architecture THINC control. Grand Opening January 12-14, 2010. , ... Charlotte, NC (PRWEB) November 9, 2009 ...
... HUYA Bioscience International, a leader in ... partnership with the School of Medicine and Pharmacy, ... in a series of collaborations that HUYA has ... to enable and accelerate the global development and ...
... Nov. 8 Today, the nation Mayors commended the ... Care for America Act, a historic piece of legislation, ... , In June, at the US Conference of Mayors ... nation unanimously supported the health care reform principles of ...
... finds , SUNDAY, Nov. 8 (HealthDay News) -- Your mother ... up straight: New research suggests that good posture could make ... of us were taught that sitting up straight gives a ... study and a psychology professor at Ohio State University, said ...
... Nov. 7 Tonight the House of Representatives passed ... reform legislation that will ensure every American has access ... The legislation, which cracks down on some of the ... million Americans and cut the deficit by $104 billion ...
Cached Medicine News:Health News:Okuma America Corporation & Hartwig, Inc. to Provide Machines to Davis Applied Technology College for Machine Tool Technology Program 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:The Nation's Mayors Commend House Passage of Health Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: